Axsome Form 144: 6,000-Share Affiliate Notice

Axsome Therapeutics submitted a Form 144 notice for the proposed sale of 6,000 shares of Common stock by an affiliate.

Rhea-AI Filing Summary

Axsome Therapeutics submitted a Form 144 notice for the proposed sale of 6,000 shares of Common stock by an affiliate. The filing shows a prior sale of 6,000 shares on 05/29/2026 with a value listed as $1,400,783.00.

Shares outstanding are listed as 51,459,766 as of 06/01/2026 in the excerpt.

Insights

Securities Counsel

Form 144 notice filed for an affiliate sale of 6,000 shares.

The filing records a proposed sale of 6,000 shares of Common stock and references a prior disposition on 05/29/2026 with a value of $1,400,783.00. This is a routine affiliate disclosure under Rule 144.

Timing, method of sale, and who will receive proceeds are not specified in the excerpt; subsequent transaction details will appear in public trade records or later filings.

Key Figures

Proposed sale: 6,000 shares Prior sale reported: 6,000 shares Value shown for prior sale: $1,400,783.00 +1 more

4 metrics

Proposed sale 6,000 shares Form 144 proposed sale listed in excerpt

Prior sale reported 6,000 shares Disposition dated <date>05/29/2026</date>

Value shown for prior sale <money>$1,400,783.00</money> <date>05/29/2026</date> line in excerpt

Shares outstanding 51,459,766 Listed as of <date>06/01/2026</date>

Key Terms

Form 144, Rule 144, shares outstanding

3 terms

Form 144 regulatory

"Form 144 notice for the proposed sale of 6,000 shares"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Rule 144 regulatory

"proposed sale under Form 144 notice (implied regulatory context)"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

shares outstanding financial

"51,459,766 as of 06/01/2026"

Shares outstanding are the total number of a company’s stock units held by all shareholders, including institutional investors and company insiders — think of them as the total number of slices of the company’s ownership pie. Investors use this number to calculate how much of the company each share represents, and it directly affects per-share measures like earnings per share, ownership percentage and valuation; when the slice count changes, an investor’s claim and the company’s per-share metrics change too.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Axsome Therapeutics' Form 144 for 6,000 shares mean?

It notifies the SEC of a proposed affiliate sale of 6,000 shares. The notice signals an affiliate intends to sell shares under Rule 144 and provides transaction timing and quantity details for public record.

Who is listed as the filer on the Form 144 for AXSM?

The excerpt lists Mark Coleman with an address at One World Trade Center. The filing shows the reporting party and contact address associated with the proposed sale.

Does the filing show prior sales for Axsome (AXSM)?

Yes, it shows a sale on 05/29/2026 of 6,000 shares with a value listed as $1,400,783.00. That prior disposition is included in the Form 144 excerpt.

How many shares outstanding does Axsome report in the excerpt?

The excerpt lists 51,459,766 shares outstanding as of 06/01/2026. This figure appears in the filing content as a baseline company-wide share count.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 04:05 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001658379
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Axsome Therapeutics, Inc.
SEC File Number	001-37635
Address of Issuer	ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NEW YORK 10007
Phone	(212) 332-3241
Name of Person for Whose Account the Securities are To Be Sold	Coleman Mark
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	6000	1381798.00	51459766	06/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/19/2024	Exercise and Hold	Axsome Therapeutics, Inc.			6000	11/19/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MARK COLEMAN ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	05/29/2026	6000	1400783.00

144: Remarks and Signature

Remarks
Date of Notice	06/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/27/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	MARK COLEMAN
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)